176 related articles for article (PubMed ID: 16391869)
1. Thymidine kinase 1: a proliferation marker for determining prognosis and monitoring the surgical outcome of primary bladder carcinoma patients.
Zhang J; Jia Q; Zou S; Zhang P; Zhang X; Skog S; Luo P; Zhang W; He Q
Oncol Rep; 2006 Feb; 15(2):455-61. PubMed ID: 16391869
[TBL] [Abstract][Full Text] [Related]
2. Thymidine kinase activity in serum of renal cell carcinoma patients is a useful prognostic marker.
Luo P; He E; Eriksson S; Zhou J; Hu G; Zhang J; Skog S
Eur J Cancer Prev; 2009 Jun; 18(3):220-4. PubMed ID: 19282758
[TBL] [Abstract][Full Text] [Related]
3. Transient increase in serum thymidine kinase 1 within one week after surgery of patients with carcinoma.
Li Z; Wang Y; Ma J; He J; Zhou J; He E; Skog S
Anticancer Res; 2010 Apr; 30(4):1295-9. PubMed ID: 20530443
[TBL] [Abstract][Full Text] [Related]
4. Prognostic significance of thymidine kinase activity in bladder carcinoma.
Mizutani Y; Wada H; Yoshida O; Fukushima M; Kamoi K; Miki T
Cancer; 2002 Nov; 95(10):2120-5. PubMed ID: 12412165
[TBL] [Abstract][Full Text] [Related]
5. Serum tumor markers may predict overall and disease specific survival in patients with clinically organ confined invasive bladder cancer.
Margel D; Tal R; Baniel J
J Urol; 2007 Dec; 178(6):2297-300; discussion 2300-1. PubMed ID: 17936837
[TBL] [Abstract][Full Text] [Related]
6. Serum thymidine kinase 1 is a prognostic and monitoring factor in patients with non-small cell lung cancer.
Li HX; Lei DS; Wang XQ; Skog S; He Q
Oncol Rep; 2005 Jan; 13(1):145-9. PubMed ID: 15583816
[TBL] [Abstract][Full Text] [Related]
7. Prognostic factors for primary superficial transitional cell carcinoma of the bladder: a retrospective cohort study.
Yang TB; Zeng FH; Sun ZQ
Chin Med J (Engl); 2006 Nov; 119(21):1821-8. PubMed ID: 17097038
[TBL] [Abstract][Full Text] [Related]
8. Outcomes of surgical treatment for upper urinary tract transitional cell carcinoma: comparison of retroperitoneoscopic and open nephroureterectomy.
Taweemonkongsap T; Nualyong C; Amornvesukit T; Leewansangtong S; Srinualnad S; Chaiyaprasithi B; Sujijantararat P; Tantiwong A; Soontrapa S
World J Surg Oncol; 2008 Jan; 6():3. PubMed ID: 18194580
[TBL] [Abstract][Full Text] [Related]
9. Effect of vascular endothelial growth factor and its receptor inhibitor on proliferation and invasion in bladder cancer.
Nakanishi R; Oka N; Nakatsuji H; Koizumi T; Sakaki M; Takahashi M; Fukumori T; Kanayama HO
Urol Int; 2009; 83(1):98-106. PubMed ID: 19641368
[TBL] [Abstract][Full Text] [Related]
10. Serum thymidine kinase 1 correlates to clinical stages and clinical reactions and monitors the outcome of therapy of 1,247 cancer patients in routine clinical settings.
Chen Y; Ying M; Chen Y; Hu M; Lin Y; Chen D; Li X; Zhang M; Yun X; Zhou J; He E; Skog S
Int J Clin Oncol; 2010 Aug; 15(4):359-68. PubMed ID: 20354751
[TBL] [Abstract][Full Text] [Related]
11. Combined determination of plasma MMP2, MMP9, and TIMP1 improves the non-invasive detection of transitional cell carcinoma of the bladder.
Staack A; Badendieck S; Schnorr D; Loening SA; Jung K
BMC Urol; 2006 Aug; 6():19. PubMed ID: 16901349
[TBL] [Abstract][Full Text] [Related]
12. Oncological outcome of retroperitoneoscopic nephroureterectomy for upper urinary tract transitional cell carcinoma.
Okegawa T; Odagane A; Ide H; Horie S; Nutahara K; Higashihara E
Int J Urol; 2006 May; 13(5):493-7. PubMed ID: 16771714
[TBL] [Abstract][Full Text] [Related]
13. Pathologic features of bladder tumors after nephroureterectomy or segmental ureterectomy for upper urinary tract transitional cell carcinoma.
Raman JD; Sosa RE; Vaughan ED; Scherr DS
Urology; 2007 Feb; 69(2):251-4. PubMed ID: 17320658
[TBL] [Abstract][Full Text] [Related]
14. [Characteristics of recurrence of T1G3 transitional cell carcinoma of bladder].
Zhang YS; Li HZ; Zhang RQ; Shi BB
Zhonghua Yi Xue Za Zhi; 2006 May; 86(19):1305-8. PubMed ID: 16796897
[TBL] [Abstract][Full Text] [Related]
15. Cytosolic thymidine kinase is a specific histopathologic tumour marker for breast carcinomas.
He Q; Mao Y; Wu J; Decker C; Merza M; Wang N; Eriksson S; Castro J; Skog S
Int J Oncol; 2004 Oct; 25(4):945-53. PubMed ID: 15375544
[TBL] [Abstract][Full Text] [Related]
16. [Surgical treatment for 217 patients with bladder transitional carcinoma].
Yu SL; Zhou FJ; Qin ZK; Han H; Liu ZW; Wang B; Wang H; Li YH
Ai Zheng; 2006 Jan; 25(1):73-5. PubMed ID: 16405754
[TBL] [Abstract][Full Text] [Related]
17. Interleukin-6/10 ratio as a prognostic marker of recurrence in patients with intermediate risk urothelial bladder carcinoma.
Cai T; Mazzoli S; Meacci F; Tinacci G; Nesi G; Zini E; Bartoletti R
J Urol; 2007 Nov; 178(5):1906-11;discussion 1911-2. PubMed ID: 17868727
[TBL] [Abstract][Full Text] [Related]
18. Low incidence of perioperative chemotherapy for stage III bladder cancer 1998 to 2003: a report from the National Cancer Data Base.
David KA; Milowsky MI; Ritchey J; Carroll PR; Nanus DM
J Urol; 2007 Aug; 178(2):451-4. PubMed ID: 17561135
[TBL] [Abstract][Full Text] [Related]
19. Lymphovascular invasion in transurethral resection specimens as predictor of progression and metastasis in patients with newly diagnosed T1 bladder urothelial cancer.
Cho KS; Seo HK; Joung JY; Park WS; Ro JY; Han KS; Chung J; Lee KH
J Urol; 2009 Dec; 182(6):2625-30. PubMed ID: 19836779
[TBL] [Abstract][Full Text] [Related]
20. Long-term follow-up of patients with Stage T1 high-grade transitional cell carcinoma managed by Bacille Calmette-Guérin immunotherapy.
Margel D; Tal R; Golan S; Kedar D; Engelstein D; Baniel J
Urology; 2007 Jan; 69(1):78-82. PubMed ID: 17270621
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
